2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷) : 2021-12-04±³À°ÀÏÀÚ : 2021-12-04
±³À°Àå¼Ò : µå·¡°ï½ÃƼ ÇѶóȦ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ :
retina@retina.or.kr ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 7ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í Á¤È¸¿ø(2020³âµµ ¿¹ºñȸ¿ø Æ÷ÇÔ): µî·Ïºñ ¸éÁ¦(¿¬È¸ºñ ³³ºÎÀÚ¿¡ ÇÑÇÔ) ÇöÁ÷ Àü°øÀÇ ¹× Æç·Î¿ì 4¸¸¿ø ±× ¿Ü 6¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-04 ÇѶóȦ 09:00~09:08 Associations between choriocapillaris flow on optical coherence tomography angiography and cardiovascular risk profile in patients with acute myocardial infarction ½Å¿ë¿î(ÇѾç´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:08~09:16 Close correlation between renal function and choroidal thickness ±èÁöÅÃ(Áß¾Ó´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:16~09:24 ÀüÀ̼º ¾È±¸³» Á¾¾ç ±è¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:24~09:32 A case of atypical necrotizing viral retinitis in patient with acquired immunodeficiency syndrome ±è·¡¿µ(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:32~09:40 Intraocular Inflammation Occurrence After The Use Of Anti-adhesion Agents ÀÌ»óÁØ(°í½Å´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:40~09:48 Inner Retinal Changes in Eyes with Hydroxychloroquine Retinopathy ¾È¼ºÁØ(ÇѾç´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 09:48~09:56 SARS-CoV-2 vaccine-induced RVO and submacular hemorrhage in AMD À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:00~10:09 Development of intraretinal fluid in neovascular age-related macular degeneration during anti-vascular endothelial growth factor treatment Á¶ÇÑÁÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:08~10:16 A novel findings of morphologic characteristics of neovascular AMD with tolerable subretinal fluid À̺´·Î(ÇѾç´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:16~10:24 Predictors of retinal fluid after anti-VEGF treatment of neovascular age-related macular degeneration: post hoc analysis from the PROOF stud »ç°ø¹Î(¿µ³²´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:24~10:32 ¸Æ¶ô¸·ºñÈÄ(pachychoroid) ´«¿¡¼ ³ë¸¥ÀÚ¸ð¾ç º´º¯(vitielliform lesion) ÀÌ¿ø±â(´©³×¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:32~10:40 »ïÃ⼺ ³ªÀÌ°ü·Ã Ȳ¹Ýº¯¼º ȯÀÚÀÇ ½Å»ýÇ÷°ü ¹®ÇÕ¿¡ ´ëÇÑ Á¤·®Àû ºÐ¼®°ú Àç¹ßºóµµ¿ÍÀÇ ¿¬°ü¼º ÀÌÇü¿ì(°Ç±¹´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:40~10:48 Ä¡·á°¡ Áß´ÜµÈ ½À¼º ³ªÀÌ°ü·ÃȲ¹Ýº¯¼º¿¡¼ °æ°ú°üÂû Áß ¹ß»ýÇÏ´Â ¸Á¸·ÇÏÃâÇ÷ ±èÀçÈÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 10:48~10:56 Looking inside the exudative age-related macular degeneration at an aspect of non-exudative AMD À±Ã¶¹Î(°í·Á´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 11:00~11:23 Ȳ¹Ý¼ö¼ú¿¡¼ ¿ì¸®°¡ °í·ÁÇÏÁö ¾Ê¾Ò´ø »çÇ×µé ±è¼øÇö(´©³×¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 11:23~11:46 Automated segmentation and prediction of OCT images using deep learning in AMD ±èÇüÂù(°Ç±¹´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 11:46~12:09 PCV: A mysterious disease ÀÌ¿ø±â(´©³×¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 13:25~13:23 OCT alone is sufficient À̹̿¬(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 13:23~13:41 OCT-A is necessary for better decision Á¶ÇÑÁÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12-04 ÇѶóȦ 13:41~13:49 #NAME? ¹è°ÇÈ£(¼¿ï´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 13:49~13:57 I prefer oral mineralocorticoid or anti-VEGF ÇÑ¿ë¼·(°æ»ó´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 13:57~14:05 #NAME? ±èÀ±Àü(¿ï»ê´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:05~14:13 I try IV thrombolysis ¿ì¼¼ÁØ(¼¿ï´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:13~14:19 Scleral buckling À̽¿ì(µ¿±¹´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:19~14:25 Vitrectomy ÀÌ¿µÈÆ(°Ç¾ç´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:25~14:32 Combined SB & vitrectomy Áö¿µ¼®(Àü³²´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:32~14:40 Prophylactic 360¡Æ laser is useful in preventing post-op RRD °½Â¹ü(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:40~14:48 There is no reason to perform 360¡Æ prophylactic laser ±èÀÀ¼®(°æÈñ´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 14:51~15:07 Ultra-widefield imaging »ç°ø¹Î(¿µ³²´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 15:07~15:19 Vitreoretinal surgery ¹Úµ¿È£(°æºÏ´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 15:19~15:31 Gene therapy for RPE65 mutation-associated retinal dystrophy ±è»óÁø(¼º±Õ°ü´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 15:31~15:43 What¡¯s new in hereditary retinal diseases ¾ÈÁöÀ±(¼¿ï´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 15:43~15:51 Epidemiology in Retina Áöµ¿Çö(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 15:51~16:07 What¡¯s new in ocular oncology ±è¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:15~16:23 °øÅëÀÚ·á¸ðµ¨À» ÀÌ¿ëÇÑ ¾È°ú ¿µ¿ª ¿¬±¸ÀÇ Ãʱ⠰æÇèµé - ¹ß»ý·ü ¿¬±¸, Ä¡·á ºÎ´ã ¹× Ä¡·á ÆÐÅÏ¿¡ ´ëÇÑ ¿¬±¸ µî 3°³ ¿¬±¸ °á°ú¸¦ Áß½ÉÀ¸·Î ¹Ú»óÁØ(¼¿ï´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:23~16:31 OCT & OCTA: where are we now? ÀÌÁÖÀº(Á¦¾È°ú)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:31~16:39 Three Monthly Intravitreal Anti-VEGF Injections with Panretinal Photocoagulation for High-Risk Proliferative Diabetic Retinopathy ¹èÁ¤ÈÆ(¼º±Õ°ü´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:39~16:47 Automated Segmentation of Retinal Capillary Non-Perfusion and Neovascularization on Ultra-Wide-Field Retinal Fluorescein Angiography of Diabetic Retinopathy using Deep Learning ¹éÁö¿ø(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:47~16:51 A Study of the Association Between Retinal Vessel Geometry and Optical Coherence Tomography Angiography Metrics in Diabetic Retinopathy ¸¶´ëÁß(ÇѸ²´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 16:51~17:03 Serum and aqueous humor adiponectin levels correlate with diabetic retinopathy development and progression ¾çÇö½Â(½Å¼¼°è¾È°ú)
±³À°½Ã°£ 12-04 ÇѶóȦ 17:03~17:11 Áß½ÉÀå¾×¼º¸Æ¶ô¸Á¸·º´Áõ ȯÀÚ¿¡¼ Ȳ¹Ý ¹× À¯µÎÁÖÀ§ ¸Æ¶ô¸· Ư¡ ºñ±³ ±è¿µÈ£(°í·Á´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 17:11~17:19 The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial ³ë¿µÁ¤(°¡Å縯´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 17:25~17:35 Çмú»ó °¿¬ À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12-04 ÇѶóȦ 17:35~17:45 Çмú»ó °¿¬ ÀÓÇüºó(´ëÀü¸í¾È°ú)